WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H564360
CAS#: NONE
Description: V4-015 is a potent inhibitor of FGFR4 kinase activity.
Hodoodo Cat#: H564360
Name: V4-015
CAS#: NONE
Chemical Formula: C26H30ClN9OS
Exact Mass: 551.20
Molecular Weight: 552.100
Elemental Analysis: C, 56.56; H, 5.48; Cl, 6.42; N, 22.83; O, 2.90; S, 5.81
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: V4015; V4 015; V4-015
IUPAC/Chemical Name: 2-(4-(6-Chloro-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)-N-(thiazol-2-yl)acetamide
InChi Key: OHQOURUADKYVHS-UHFFFAOYSA-N
InChi Code: InChI=1S/C26H30ClN9OS/c1-33-7-11-35(12-8-33)19-4-2-18(3-5-19)24-31-22-23(20(27)16-29-25(22)32-24)36-13-9-34(10-14-36)17-21(37)30-26-28-6-15-38-26/h2-6,15-16H,7-14,17H2,1H3,(H,28,30,37)(H,29,31,32)
SMILES Code: O=C(NC1=NC=CS1)CN2CCN(C3=C4C(NC(C5=CC=C(N6CCN(C)CC6)C=C5)=N4)=NC=C3Cl)CC2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 552.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Ho HK, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, Breza N, Greff Z, Horváth Z, Pató J, Szabadkai I, Szokol B, Baska F, Őrfî L, Ullrich A, Kéri G, Chua BT. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Curr Med Chem. 2013;20(10):1203-17. PubMed PMID: 23409720.